|
1
|
Kuhnt D, Becker A, Ganslandt O, Bauer M,
Buchfelder M and Nimsky C: Correlation of the extent of tumor
volume resection and patient survival in surgery of glioblastoma
multiforme with high-field intraoperative MRI guidance. Neuro
Oncol. 13:1339–1348. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Houdek Z, Cendelín J, Kulda V, Babuška V,
Cedíková M, Králíčková M, Pacherník J, Stefano GB and Vožeh F:
Intracerebellar application of P19-derived neuroprogenitor and
naive stem cells to Lurcher mutant and wild type B6CBA mice. Med
Sci Monit. 18:BR174–BR180. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumours of the central nervous system. Acta
Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ehtesham M, Stevenson CB and Thompson RC:
Stem cell therapies for malignant glioma. Neurosurg Focus.
19:E52005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Omuro A and DeAngelis LM: Glioblastoma and
other malignant gliomas: A clinical review. JAMA. 310:1842–1850.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schwartzbaum JA, Fisher JL, Aldape KD and
Wrensch M: Epidemiology and molecular pathology of glioma. Nat Clin
Pract Neurol. 2:494–503. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: European Organisation for Research and Treatment of
Cancer Brain Tumor and Radiotherapy Groups; National Cancer
Institute of Canada Clinical Trials Group: Radiotherapy plus
concomitant and adjuvant temozolomide for glioblastoma. N Engl J
Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wen PY and Kesari S: Malignant gliomas in
adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen R, Nishimura MC, Bumbaca SM,
Kharbanda S, Forrest WF, Kasman IM, Greve JM, Soriano RH, Gilmour
LL, Rivers CS, et al: A hierarchy of self-renewing tumor-initiating
cell types in glioblastoma. Cancer Cell. 17:362–375. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wibom C, Späth F, Dahlin AM, Langseth H,
Hovig E, Rajaraman P, Johannesen TB, Andersson U and Melin B:
Investigation of established genetic risk variants for glioma in
prediagnostic samples from a population-based nested case-control
study. Cancer Epidemiol Biomarkers Prev. 24:810–816. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kasinski AL and Slack FJ: Epigenetics and
genetics. MicroRNAs en route to the clinic: Progress in validating
and targeting microRNAs for cancer therapy. Nat Rev Cancer.
11:849–864. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang L, Li Q, Wang Q, Jiang Z and Zhang L:
Silencing of miRNA-218 promotes migration and invasion of breast
cancer via Slit2-Robo1 pathway. Biomed Pharmacother. 66:535–540.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chan JA, Krichevsky AM and Kosik KS:
MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells.
Cancer Res. 65:6029–6033. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kloosterman WP and Plasterk RH: The
diverse functions of microRNAs in animal development and disease.
Dev Cell. 11:441–450. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Treiber T, Treiber N and Meister G:
Regulation of microRNA biogenesis and function. Thromb Haemost.
107:605–610. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Friedman RC, Farh KK, Burge CB and Bartel
DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome
Res. 19:92–105. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang K, Wang X, Zou J, Zhang A, Wan Y, Pu
P, Song Z, Qian C, Chen Y, Yang S, et al: miR-92b controls glioma
proliferation and invasion through regulating Wnt/beta-catenin
signaling via Nemo-like kinase. Neuro Oncol. 15:578–588. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hu X, Chen D, Cui Y, Li Z and Huang J:
Targeting microRNA-23a to inhibit glioma cell invasion via HOXD10.
Sci Rep. 3:34232013.PubMed/NCBI
|
|
19
|
Wu D, Zhou Y, Pan H, Zhou J, Fan Y and Qu
P: microRNA-99a inhibiting cell proliferation, migration and
invasion by targeting fibroblast growth factor receptor 3 in
bladder cancer. Oncol Lett. 7:1219–1224. 2014.PubMed/NCBI
|
|
20
|
Chen Y, Gao DY and Huang L: In vivo
delivery of miRNAs for cancer therapy: Challenges and strategies.
Adv Drug Deliv Rev. 81:128–141. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Medina PP, Nolde M and Slack FJ: OncomiR
addiction in an in vivo model of microRNA-21-induced pre-B-cell
lymphoma. Nature. 467:86–90. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Obad S, dos Santos CO, Petri A, Heidenblad
M, Broom O, Ruse C, Fu C, Lindow M, Stenvang J, Straarup EM, et al:
Silencing of microRNA families by seed-targeting tiny LNAs. Nat
Genet. 43:371–378. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Saito Y, Liang G, Egger G, Friedman JM,
Chuang JC, Coetzee GA and Jones PA: Specific activation of
microRNA-127 with downregulation of the proto-oncogene BCL6 by
chromatin-modifying drugs in human cancer cells. Cancer Cell.
9:435–443. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu N and Tu Y: Systematic review of
microRNAs and its therapeutic potential in glioma. Cancer Transl
Med. 1:50–66. 2015. View Article : Google Scholar
|
|
25
|
Liu K, Liu S, Zhang W, Jia B, Tan L, Jin Z
and Liu Y: miR-494 promotes cell proliferation, migration and
invasion, and increased sorafenib resistance in hepatocellular
carcinoma by targeting PTEN. Oncol Rep. 34:1003–1010.
2015.PubMed/NCBI
|
|
26
|
Guo T, Yu W, Lv S, Zhang C and Tian Y:
MiR-302a inhibits the tumorigenicity of ovarian cancer cells by
suppression of SDC1. Int J Clin Exp Pathol. 8:4869–4880.
2015.PubMed/NCBI
|
|
27
|
Wei ZJ, Tao ML, Zhang W, Han GD, Zhu ZC,
Miao ZG, Li JY and Qiao ZB: Up-regulation of microRNA-302a
inhibited the proliferation and invasion of colorectal cancer cells
by regulation of the MAPK and PI3K/Akt signaling pathways. Int J
Clin Exp Pathol. 8:4481–4491. 2015.PubMed/NCBI
|
|
28
|
Zhang GM, Bao CY, Wan FN, Cao DL, Qin XJ,
Zhang HL, Zhu Y, Dai B, Shi GH and Ye DW: MicroRNA-302a suppresses
tumor cell proliferation by inhibiting AKT in prostate cancer. PLoS
One. 10:e01244102015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liang Z, Bian X and Shim H: Inhibition of
breast cancer metastasis with microRNA-302a by downregulation of
CXCR4 expression. Breast Cancer Res Treat. 146:535–542. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhao L, Wang Y, Jiang L, He M, Bai X, Yu L
and Wei M: MiR-302a/b/c/d cooperatively sensitizes breast cancer
cells to adriamycin via suppressing P-glycoprotein (P-gp) by
targeting MAP/ERK kinase kinase 1 (MEKK1). J Exp Clin Cancer Res.
35:252016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang Y, Zhao L, Xiao Q, Jiang L, He M, Bai
X, Ma M, Jiao X and Wei M: miR-302a/b/c/d cooperatively inhibit
BCRP expression to increase drug sensitivity in breast cancer
cells. Gynecol Oncol. 141:592–601. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nishida K and Hirano T: The role of Gab
family scaffolding adapter proteins in the signal transduction of
cytokine and growth factor receptors. Cancer Sci. 94:1029–1033.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hibi M and Hirano T: Gab-family adapter
molecules in signal transduction of cytokine and growth factor
receptors, and T and B cell antigen receptors. Leuk Lymphoma.
37:299–307. 2000.PubMed/NCBI
|
|
34
|
Wöhrle FU, Daly RJ and Brummer T:
Function, regulation and pathological roles of the Gab/DOS docking
proteins. Cell Commun Signal. 7:222009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ding CB, Yu WN, Feng JH and Luo JM:
Structure and function of Gab2 and its role in cancer (Review). Mol
Med Rep. 12:4007–4014. 2015.PubMed/NCBI
|
|
36
|
Chen Y, Liu Q, Wu M, Li M, Ding H, Shan X,
Liu J, Tao T, Ni R and Chen X: GAB2 promotes cell proliferation by
activating the ERK signaling pathway in hepatocellular carcinoma.
Tumour Biol. 37:11763–11773. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Duckworth C, Zhang L, Carroll SL, Ethier
SP and Cheung HW: Overexpression of GAB2 in ovarian cancer cells
promotes tumor growth and angiogenesis by upregulating chemokine
expression. Oncogene. 35:4036–4047. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ding C, Luo J, Yu W, Gao S, Yang L, Chen C
and Feng J: Gab2 is a novel prognostic factor for colorectal cancer
patients. Int J Clin Exp Pathol. 8:2779–2786. 2015.PubMed/NCBI
|
|
39
|
Fleuren ED, O'Toole S, Millar EK, McNeil
C, Lopez-Knowles E, Boulghourjian A, Croucher DR, Schramek D,
Brummer T, Penninger JM, et al: Overexpression of the oncogenic
signal transducer Gab2 occurs early in breast cancer development.
Int J Cancer. 127:1486–1492. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Shi L, Sun X, Zhang J, Zhao C, Li H, Liu
Z, Fang C, Wang X, Zhao C, Zhang X, et al: Gab2 expression in
glioma and its implications for tumor invasion. Acta Oncol.
52:1739–1750. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tian LQ, Liu EQ, Zhu XD, Wang XG, Li J and
Xu GM: MicroRNA-197 inhibits cell proliferation by targeting GAB2
in glioblastoma. Mol Med Rep. 13:4279–4288. 2016.PubMed/NCBI
|
